Literature DB >> 1313611

Induction of tubuloreticular structures in cultured human endothelial cells by recombinant interferon alfa and beta.

S P Hammar1, J Y Luu, D E Bockus, F L Remington, J W Luu, S Friedman, M A Bean.   

Abstract

Tubuloreticular structures were induced in human umbilical vein endothelial cells cultured in media containing recombinant interferon alfa and beta but not in media containing recombinant interferon gamma or other agents that induce interferon, such as 5-bromodeoxyuridine or polyinosinicpolycytidylic acid. Recombinant interferon beta induced tubuloreticular structures in endothelial cells at a lower concentration and in a greater percentage of cell sections than recombinant interferon alfa. This report of tubuloreticular structures being induced in vitro in nonlymphoid cells provides evidence that interferon is the substance that causes the formation of tubuloreticular structures in endothelial cells in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1313611     DOI: 10.3109/01913129209074562

Source DB:  PubMed          Journal:  Ultrastruct Pathol        ISSN: 0191-3123            Impact factor:   1.094


  3 in total

Review 1.  Bromodeoxyuridine: a diagnostic tool in biology and medicine, Part III. Proliferation in normal, injured and diseased tissue, growth factors, differentiation, DNA replication sites and in situ hybridization.

Authors:  F Dolbeare
Journal:  Histochem J       Date:  1996-08

2.  Tubuloreticular Inclusions in Renal Allografts Associate with Viral Infections and Donor-Specific Antibodies.

Authors:  Michelle Willicombe; Jill Moss; Linda Moran; Paul Brookes; Eva Santos-Nunez; Adam G McLean; Thomas Cairns; David Taube; Terence H Cook; Candice Roufosse
Journal:  J Am Soc Nephrol       Date:  2015-11-27       Impact factor: 10.121

3.  Case Report: CMV-Associated Congenital Nephrotic Syndrome.

Authors:  Anju Jacob; Shameer M Habeeb; Leal Herlitz; Eva Simkova; Jwan F Shekhy; Alan Taylor; Walid Abuhammour; Ahmad Abou Tayoun; Martin Bitzan
Journal:  Front Pediatr       Date:  2020-11-27       Impact factor: 3.418

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.